Plasma Epstein-Barr virus (EBV) DNA: Role as a screening test for nasopharyngeal carcinoma (NPC)?

International Journal of Cancer

Volumn 117, Issue 3, 2005, Pages 515-516

  Wong, Lei P ^a   Lai, Kristi T W ^a   Tsui, Elaine ^a   Kwong, Kwok H ^a   Tsang, Raymond H N ^a   Ma, Edmond S K ^a  

^a HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

BLOOD SAMPLING; CANCER SCREENING; DNA DETERMINATION; EARLY DIAGNOSIS; EPSTEIN BARR VIRUS; HUMAN; LETTER; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCREENING TEST;

DNA, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; MASS SCREENING; NASOPHARYNGEAL NEOPLASMS;

EID: 26444484529     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21194     Document Type: Letter

References (10)

1. Ng WT, Yau TK, Yung RW, Sze WM, Tsang AH, Law AL, Lee AW. Screening for family members of patients with nasopharyngeal carcinoma. Int J Cancer 2005;113:998-1001.
2. Zeng Y, Zhong JM, Li LY, Wang PZ, Tang H, Ma YR, Zhu JS, Pan WJ, Liu YX, Wei ZN. Follow-up studies on Epstein-Barr virus IgA/VCA antibody-positive persons in Zangwu County, China. Intervirology 1983;20:1990-4.
3. Zeng Y, Zhang LG, Li HY, Jan MG, Zhang Q, Wu YC, Wang YS, Su GR. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer 1982;29:139-41.
4. Zeng Y, Zhang LG, Wu YC, Huang YS, Huang NQ, Li JY, Wang YB, Jiang MK, Fang Z, Meng NN. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer 1985;36:545-7.
5. Tsang RK, Vlantis AC, Ho RW, Tarn JS, To KF, van Hasselt CA. Sensitivity and specificity of Epstein-Barr virus IgA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review. Head Neck 2004;26:598-602.
6. Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, Lee CK, Hjelm MN, Johnson PJ, Huang P. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59:1188-91.
7. Lo YM, Chan AT, Chan LY, Leung SF, Lam CW, Huang DP, Johnson PJ. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 2000;60:6878-81.
8. Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, Mo F, Lai M, Ho S, Huang DP, Johnson PJ. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002;94:1614-9.
9. Fan H, Nicholls J, Chua D, Chan KH, Sham J, Lee S, Gulley ML. Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus. Int J Cancer 2004;112:1036-41.
10. Fan H, Gulley ML. Epstein-Barr viral load measurement as a marker of EBV-related disease. Mol Diagn 2001;6:279-89.